ESC 365 - Insights on the value of biomarkers in the management of transthyretin amyloid cardiomyopathy (ATTR-CM)

Open Access

Insights on the value of biomarkers in the management of transthyretin amyloid cardiomyopathy (ATTR-CM)

Session: Evolving landscape in transthyretin amyloid cardiomyopathy (ATTR-CM): clinical practice and emerging treatments

Topic: Cardiomyopathies

Speaker: Doctor P. Garcia-Pavia (Majadahonda, ES)

Sponsored by BridgeBio

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Pablo Garcia-Pavia

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)

62 presentations

15 followers

4 more presentations in this session

Welcome and Introductions

Speaker: Doctor F. Cappelli (Florence, IT)

Emerging trends in the clinical practice of transthyretin amyloid cardiomyopathy (ATTR-CM)

Speaker: Professor M. Fontana (London, GB)

Perspectives on current & future pharmacological treatments of transthyretin amyloid cardiomyopathy (ATTR-CM)

Speaker: Doctor J. Gillmore (Greater London, GB)

Panel discussion

Speaker: Doctor F. Cappelli (Florence, IT)

Access the full session

Evolving landscape in transthyretin amyloid cardiomyopathy (ATTR-CM): clinical practice and emerging treatments

Speakers: Doctor P. Garcia-Pavia, Doctor F. Cappelli, Professor M. Fontana, Doctor J. Gillmore, Doctor F. Cappelli

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources